The authors estimate that at least 18.5 serious adverse events could occur for every COVID- 19 hospitalization prevented.

From January 2021 to the time of writing, 1598 athletes suffered cardiac arrest, 1101 of which with deadly outcome.8 Notably, in a 38-years timespan (1966-2004), 1101 athletes under the age of 35 died (~29/years) due to various heart- related conditions, 50% of whom had congenital anatomical heart disease and cardiomyopathies and 10% had atherosclerotic heart disease with early onset.9

According to a study done on 301 teenagers between the ages of 13 and 18 who had received two doses of the Pfizer/BioNTech vaccine, 29.24% of participants experienced cardiovascular complications such tachycardia, palpitations and 2.33% suffered myopericarditis.10

It is noteworthy, that no statistically significant in-crease in the incidence of myocarditis or pericarditis was observed in un-vaccinated subjects after SARS-CoV- 2 infection, in a large population study.11

Since the end of 2021 and throughout 2022, young age excess mortality has substantially increased in many European countries (Figure1), in concert with the vaccine program.12

In conclusion we thank our colleagues for advancing the discourse on the extremely concerning safety data after COVID- 19 vaccination, which prompt us to empha-size again and more firmly the need of biodistribution studies as well as of rational harm- benefit assessments by age group